Futura Medical Share Discussion Threads

[lbo] 14/12/2022 13:58

Even Med3000 just as a placebo medical device gel OTC with no pharmacy assessment will be associated with deaths.https://www.gov.uk/government/news/mhra-reclassifies-viagra-connect-tablets-to-a-pharmacy-medicineThis decision was made following a reassuring assessment of the safety of the Viagra Connect, advice from the Commission on Human Medicines, and a public consultationhttps://www.nhs.uk/medicines/sildenafil-viagra/side-effects-of-sildenafil/Viagra is approved for treatment in the UK and offered by the NHS because it is a safe and effective treatment. https://bjgpopen.org/content/5/2/bjgpopen20X101145Sildenafil and tadalafil are recommended firstline treatments for erectile dysfunction (ED). Sildenafil was legally reclassified to a pharmacy medicine in the UK in 2018.The two-fold increase in the rate of primary care prescriptions in the past 10 years suggests that more men are being screened for, or seeking help for, ED. The higher rate of prescribing offers opportunity for monitoring of linked risk factors, such as diabetes mellitus, dyslipidaemia, and vascular disorders

[lbo] 14/12/2022 13:54

New FDA-Approved Labeling for Petros Pharmaceuticals’ STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy






Will MED3000 work if I have had a prostatectomy?

At this time we have not tested the product in patients who have undergone radical prostatectomy

[petroc] 14/12/2022 13:51

‘other than men suffering from severe ED with significant co-morbidities’;

Hahaha! LiarBO obviously believes that his cherished Viagra works for patients with severe ED and significant comorbidities! And how many times has he gone on about ED treatments covering up other, possibly fatal conditions? And used that as a blunt instrument to criticise MED3000 for being an OTC medication? He just makes up his lies as he goes along in a futile attempt to damage the share price and FUM. He's just a stock bashing idiot who lost all his money by invested like a schoolboy. LOL. ROFLMAO. Etc..

[lbo] 14/12/2022 13:43

‘other than men suffering from severe ED with significant co-morbidities’

So they are admitting it failed in the real world consumer test to screen out men with underlying co-morbidities! Like they said would normally have happened in the clinical setting. So they are admitting that self diagnosis of the real underlying cause of the ED can fail. Leading to very inappropriate treatment with just an OTC placebo gel product. This could have very dangerous consequences for patients. If the use of MED3000 OTC marketed as ‘clinically proven’ to treat ED. Leads some men who use MED3000 to delay in seeking a proper assessment of the real and more serious underlying causes of their ED. Which then possibly is factor which ultimately contributes to their death. Herein lies the major liability risk for Futura marketing a placebo medical device ED gel of highly questionable efficacy. Yet claiming it is ‘clinically proven’ ro treat a a very complex condition like Erectile Dysfunction. Especially when Futura cannot even substantiate that claim with any adequately controlled studies



Without medical diagnosis of the cause of the erectile dysfunction and of any potentially underlying serious medical conditions (such as CVD and diabetes), the risks associated with self-treatment of erectile dysfunction outweigh the benefits



Figures released by the British Association of Urological Surgeons show that 90 per cent of men with impotence have at least one underlying physical cause for their problem, with 40 per cent living with cardiovascular disease and 33 per cent with diabetes.

Cardiovascular disease is the leading cause of death globally, claiming an estimated 17.9 million lives each year according to the World Health Organisation.

[j777j] 14/12/2022 13:29

Consumer In-Use Test

Cooper, as part of its due diligence process, conducted a consumer marketing Home Use Test ("HUT") in the United Kingdom, France and the Netherlands whereby individuals self-diagnosed with ED were provided with a four-pack sample of MED3000. The in-use results were in line with findings published in 2019 in Futura's clinical study FM57 which showed that over two thirds of patients experienced a clinically meaningful benefit from using MED3000 in a controlled clinical setting. MED3000 performed well in the real world, consumer HUT setting, with the majority of men with ED, other than men suffering from severe ED with significant co-morbidities, seeing an improvement in erectile performance and underlining the product's potential as a highly effective, safe, clinically proven, topical treatment for ED.

[petroc] 14/12/2022 13:23

'MED3000 works as a well and for as many that believes it will work for them! Same can be said about using an arousal gel made of similar ingredients! LOL' Squawked LiarBO, excitedly and semi-literately. (Copy/pasted before he can go back and edit it heh heh heh). Hybrasil said 'don't worry LiarBO, nothing works for everybody.' In LiarBO's case, it would appear that everything works for him. There's been so many gels, compounds, unguents and ointments that LiarBO has stated work just as well as MED3000 that it's quite obvious that he's tried them all. Except of course he hasn't tried MED3000, but feels able to comment authoritatively on the subject. LOL.

[lbo] 14/12/2022 13:10

MED3000 works as well and for as many that believe it will work for them! Same can be said about using an arousal gel made of similar ingredients! LOL



A product that contemporary technology does not understand must establish that this magic, actually works. Proof is what separates an effect new to science from a swindle . . . . If a condition responds to treatment, then selling a placebo as if it had therapeutic effect directly injures the consumer



All Futura have done with MED3000 is open the door for Reckitt to sell similar lubricants/arousal gels as medical device placebo treatments for ED. And report Med3000 to the ASA, FTC etc for being misleading if it doesn’t inform consumers that MED3000 itself has no proven effect in ED beyond a placebo. As it has no proven efficacy in an adequate placebo controlled study or even against any standard cooling lubricant/arousal gels in an ED study.



‘You are the active ingredient’

Even the analysis on market forecasts knows Reckitt who is the market leader in lubricants will be only one to gain from marketing lubricants as placebo treatments for Erectile Dysfunction




Reckitt Benckiser was the defined leader and the ultimate four Personal lubricant vendors with leading brands such as Durex Play and K-Y Jelly.

KEY GROWTH FACTORS

Increasing prevalence of erectile dysfunction

9 Market Growth Enablers
9.1 Increasing Prevalence of Erectile Dysfunction

[broomrigg] 14/12/2022 12:41

Today's Trader's Cafe with Zak Mir: Bulletin Board Heroes (on Vox markets)......

(Listen from 6m 5s)

He's looking for 60p by the end of the month (note: this is just on chart analysis and does not take into account potential news flow re. revenues next year which will leave 60p in the dust).

[hybrasil] 14/12/2022 12:29

LBO

Dont worry- nothing works for everybody

[hybrasil] 14/12/2022 12:29

The uplifting nature off this product certainly seems to give the share price and the number of posts on this thread, a rise.

[lbo] 14/12/2022 12:08

So why aren’t Lombard who you publicly called ‘market manipulators’ buying it on the cheap!? You have openly accused them of selling out before fundraisings and getting inside knowledge from the company






Lombard Odier will receive a total of 10,937,500 warrants to subscribe for further new Ordinary Shares at a price of 40 pence per share, exercisable until the fifth anniversary of their issue, in respect of its participation in the Subscription.

J777J - 31 Aug 2022 - 09:31:28 - 13032 of 14796

Punters burned as usual on this stock

Lombard probably offloading into this bear market

J777J - 23 Dec 2019 - 08:45:36 - 7043 of 9296

Clearly feels like a stitch up by Lombard who shorted after the RNS knowing they would buy back in the placing? After all it was they that underwrote it. No TR1 announcement came from them. That after something near 35% to 40% of the company's shares changed hands!!! The mysterious Butler on their payroll????? This individual appeared out of the smoke as a duo act. The obvious tactic was to spread scare stories across the various bb's.Get the price as low as possible. Lombard appear as the white knight,the great saviours,but are they in fact ruthless market manipulators?

[j777j] 14/12/2022 11:19

and on and on

[j777j] 14/12/2022 11:09

So is 11.08 and lbo has already posted 12 times


Make your own minds up as what he is up to and who he is working for



He sounds ever more desperate and the share price rises



121p next stop

[j777j] 14/12/2022 11:05

Just shows how desperate LBO is


He has posted non stop 24/7 for two years

[j777j] 14/12/2022 10:59

Also fascinating to hear again from two leading ED experts that Eroxon could be used as a first line treatment for ED.

Citing speed of onset,no pre planning needed, ability to be part of forepay with partner,no dietary restrictions needed,no contraindications with other medications.



All in all a Blockbuster right in front of our eyes




Eroxon is not a PD5 inhibitor like the others which have major contraindications

[lbo] 14/12/2022 10:58

https://www.sec.gov/Archives/edgar/data/1182129/000110465914066948/a14-21083_3ex99d1.htm ED patients in my practice are looking for a safe and effective treatment option that also works fast, said Wayne JG Hellstrom, M.D., FACS, Professor of Urology at Tulane University School of Medicine in New Orleans and primary investigator for the clinical trial. "In my opinion, STENDRA can be an appropriate and important treatment option because the clinical trial demonstrated that it provides a rapid onset of action in many men in as early as approximately 15 minutes'https://www.globenewswire.com/en/news-release/2022/04/19/2424598/0/en/Petros-Pharmaceuticals-Announces-Positive-Results-of-Over-the-Counter-OTC-Label-Comprehension-Study-for-Erectile-Dysfunction-Drug-STENDRA-avanafil.html

[j777j] 14/12/2022 10:57

Interesting as now the co is in play for the massive US market.


This will filter back to the share price as potential commercial partners line up and news leaks


121p latest price target and that will be one tenth of what it will be worth if they even manage a 5% market share of a $5 billion pa market place